Merck drug shows superior cholesterol reduction in phase 3 trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. RKLB

Go back to Merck drug shows superior cholesterol reduction in phase 3 trial
Merck & Co. (NYSE: MRK) Delayed: 128.66 +3.21 (2.56%)
Previous Close $125.45    52 Week High $65.46 
Open $125.83    52 Week Low $47.97 
Day High $128.78    P/E 87.52 
Day Low $125.83    EPS $1.47 
Volume 18,891,511